- Home
- CARV vs INDP Comparison
CARV vs INDP Comparison
Compare CARV & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARV
- INDP
- Stock Information
- Founded
- CARV 1948
- INDP 2000
- Country
- CARV United States
- INDP United States
- Employees
- CARV N/A
- INDP N/A
- Industry
- CARV Savings Institutions
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- CARV Finance
- INDP Health Care
- Exchange
- CARV Nasdaq
- INDP Nasdaq
- Market Cap
- CARV 7.2M
- INDP 7.4M
- IPO Year
- CARV 1994
- INDP N/A
- Fundamental
- Price
- CARV $1.36
- INDP $0.50
- Analyst Decision
- CARV
- INDP Strong Buy
- Analyst Count
- CARV 0
- INDP 2
- Target Price
- CARV N/A
- INDP $8.50
- AVG Volume (30 Days)
- CARV 9.2K
- INDP 75.0K
- Earning Date
- CARV 02-13-2025
- INDP 05-07-2025
- Dividend Yield
- CARV N/A
- INDP N/A
- EPS Growth
- CARV N/A
- INDP N/A
- EPS
- CARV N/A
- INDP N/A
- Revenue
- CARV $24,056,000.00
- INDP N/A
- Revenue This Year
- CARV N/A
- INDP N/A
- Revenue Next Year
- CARV N/A
- INDP N/A
- P/E Ratio
- CARV N/A
- INDP N/A
- Revenue Growth
- CARV N/A
- INDP N/A
- 52 Week Low
- CARV $1.30
- INDP $0.43
- 52 Week High
- CARV $2.39
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- CARV 43.47
- INDP 39.50
- Support Level
- CARV $1.31
- INDP $0.45
- Resistance Level
- CARV $1.39
- INDP $0.53
- Average True Range (ATR)
- CARV 0.07
- INDP 0.04
- MACD
- CARV 0.00
- INDP 0.01
- Stochastic Oscillator
- CARV 28.95
- INDP 66.67
About CARV Carver Bancorp Inc.
Carver Bancorp Inc is a holding company and conducts its business as a unitary saving and loan holding firm and the business of the company consists of the operation of its subsidiary. The bank offers a wide range of financial solutions to meet customers' banking. It offers other consumer and commercial banking products and services, such as debit cards, online banking, online bill pay, and telephone banking. The company provides deposit products, such as demand, savings, and time deposits for consumers, businesses, and governmental and quasi-governmental agencies in its market area within New York City.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.